Therapy procedures have considerably improved in recent years as a result of a better knowledge of the major oncogenes and signaling pathways involved in its development and progression—for instance, molecularly targeted therapies such as the inhibitors of BRAF and MEK and immune-checkpoint blockade like anti-PD1 and CTLA-4 treatments have now significantly improved survival in these melanoma patients (3, 4). This evidence concerns the gene BRAF and melanoma.